Harrow Health Inc

Real-time Quotes | Nasdaq Last Sale

After Hours: 4.960 0 0.00% 16:00 10/27 EDT
Corp Actions
Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020
NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 financial results and host a conference call at 4:45 p.m. Eastern Standard Time / 1:45 p.m. Pacific Standard Time to discuss the financial results and recent business developments. After the close of the market on November 9, 2020, Harrow will issue a press release containing a link to its third quarter 2020 Letter to Stockholders. The Letter to Stockholders will be archived on the Harrow Investor Relations website in the Archives section, along with the preceding letters, all of which can be found by clicking here. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction, an overview of the quarter, and outlook for the business.Conference Call Details: * U.S. callers: (844) 602-0380 * International callers: (862) 298-0970 * Audio-only webcast: please click here Conference Call Replay:A dial in replay of the call will be available until December 9, 2020. The webcast replay will be available until February 09, 2021. * U.S. callers: (877) 481-4010, Replay ID: 38433 * International callers: (919) 882-2331, Replay ID: 38433 * Webcast: please click here About Harrow Health Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. Harrow also owns Mayfield Pharmaceuticals, Stowe Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, and Mayfield. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.Investor Contact:
GlobeNewswire · 8h ago
Harrow Health (HROW) Enters Oversold Territory
Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 9h ago
Harrow Health Appoints Larry Van Horn to its Board of Directors
NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors. Mark L. Baum, CEO of Harrow Health, commented, “I am honored to welcome Larry to the Harrow Health Board of Directors where his work on
GlobeNewswire · 09/30 13:00
Harrow Health Inc (HROW) Investor Presentation - Slideshow
The following slide deck was published by Harrow Health, Inc. in conjunction with this event.
Seekingalpha · 09/18 12:06
Harrow Health to Attend Lake Streets Virtual 4th Annual (BIG4) Conference September 17, 2020
NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September 17, 2020, on a virtual platform. Mark L. Baum, CEO, and Andrew Boll, CFO, will be available throughout
GlobeNewswire · 09/11 16:22
Why Harrow Health's (NASDAQ:HROW) CEO Pay Matters
Mark Baum became the CEO of Harrow Health, Inc. (NASDAQ:HROW) in 2012, and we think it's a good time to look at the...
Simply Wall St. · 09/07 20:03
Our Take On Eton Pharmaceuticals
Shares of 505(b)(2) concern Eton Pharmaceuticals, Inc. have more than doubled off their mid-March lows and are now above where they started the year.COVID-19 is hindering the launch of its one approved product (Biorphen) and the abandonment of large market opportunity candidate ET-103 has had some negative impacts.With eight late-stage candidates, Eton merited a deeper dive.A full investment analysis is provided in the paragraphs below.
Seekingalpha · 09/01 19:23
Harrow Health's Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Harrow Health.
Zacks · 08/26 13:16
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HROW. Analyze the recent business situations of Harrow Health Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HROW stock price target is 10.75 with a high estimate of 11.50 and a low estimate of 10.00.
Institutional Holdings
Institutions: 95
Institutional Holdings: 12.15M
% Owned: 47.37%
Shares Outstanding: 25.65M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Robert Kammer
Chief Executive Officer/Director
Mark Baum
Chief Financial Officer/Secretary
Andrew Boll
Corporate Executive
John Saharek
Larry Dillaha
Richard Lindstrom
Dennis Saadeh
Independent Director
Teresa Sparks
Independent Director
R. Lawrence Van Horn
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HROW
Harrow Health, Inc., formerly Imprimis Pharmaceuticals, Inc., owns diversified portfolio of healthcare businesses. The Company’s subsidiaries are Imprimis Pharmaceuticals Inc. and Park Compounding. Imprimis Pharmaceuticals Inc. is engaged in ophthalmology pharmaceutical compounding business. Park Compounding is engaged in compounding business and also offers strategic research and development facilities, which is engaged in developing and dispensing medicines for individual patients.
Hot Stocks

Webull offers kinds of Harrow Health Inc stock information, including NASDAQ:HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.